Teva migraine drug helps to contain profit fall

TEL AVIV (Reuters) - Israel-based Teva Pharmaceutical Industries posted a slightly smaller than expected drop in first-quarter profit and forecast a sharp rise in revenue next year from its new migraine drug Ajovy.The world's largest generic drugmaker is counting on Ajovy and Huntington's treatment Austedo to help to revive its fortunes after restructuring to tackle a debt crisis.Sales from its blockbuster multiple sclerosis drug Copaxone have been declining in the face of generic competition,..